Loading…
Reported covered position: November 10-October 13 with Senator Rob PortmanDecember 08-April 10 with Senator Kay Bailey HutchisonJanuary 05-March 06 with Senator Mike DeWine
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per - and polyfluoroalkyl substances (PFAS) legislation; Issues related to section 301 tariffs; Issues related to H.R.4521 - America COMPETES Act of 2022 (117th Congress).
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per - and polyfluoroalkyl substances (PFAS) legislation; Issues related to section 301 tariffs; and other China issues.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
OPTIONS CLEARING CORPORATION (OCC) via FORBES-TATE
2023 · third_quarter · Q3
Issues related to financial services and tax.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NORTHPORT HEALTH SERVICES via FORBES-TATE
2023 · third_quarter · Q3
Source: Senate LDA
| PHRMA |
| 25 |
| 2017–2023 |
| SIEMENS CORPORATION | 24 | 2016–2021 |
| A.O. SMITH CORPORATION | 21 | 2019–2023 |
| WE ARE GOLF | 21 | 2015–2021 |
| ANHEUSER-BUSCH COMPANIES, INC. | 20 | 2015–2020 |
| EMERGENT BIOSOLUTIONS | 20 | 2019–2023 |
| ASSURED GUARANTY MUNICIPAL CORP. | 19 | 2019–2023 |
| INSURED RETIREMENT INSTITUTE | 19 | 2019–2023 |
| NATIONAL MARINE MANUFACTURERS ASSOCIATION | 19 | 2017–2022 |
| NOVARTIS, INC. | 19 | 2019–2023 |
| PACIFIC GAS AND ELECTRIC | 19 | 2017–2022 |
| VIRPAX PHARMACEUTICALS | 19 | 2019–2023 |
| A PLACE FOR MOM, INC. | 18 | 2018–2022 |
| DELOITTE LLP | 18 | 2019–2023 |
| H&R BLOCK | 18 | 2015–2019 |
| ULTRAGENYX PHARMACEUTICAL | 18 | 2019–2023 |
| UNITED PARCEL SERVICE | 18 | 2017–2021 |
| BAYER CORPORATION | 17 | 2019–2022 |
| IMAGINE LEARNING | 17 | 2017–2021 |
| NATIONAL ASSOCIATION OF PROTON THERAPY | 17 | 2019–2023 |
| Sorrento Therapeutics, Inc. | 17 | 2017–2021 |
| ALEXION PHARMACEUTICALS, INC. | 16 | 2020–2023 |
| SECURE IDENTITY, LLC (DBA CLEAR) | 15 | 2019–2022 |
| VIR BIOTECHNOLOGY, INC. | 15 | 2020–2023 |
| VERDE TECHNOLOGIES | 14 | 2019–2022 |
| ABBOTT LABORATORIES | 13 | 2016–2020 |
| AMERICAN SPORTFISHING ASSOCIATION | 13 | 2017–2020 |
| PELOTON INTERACTIVE, INC. | 13 | 2021–2023 |
| THE PARTNERSHIP FOR AMERICAS HEALTH CARE FUTURE | 12 | 2019–2021 |
| TRUE VELOCITY | 12 | 2019–2021 |
| AMERICAN HONDA MOTOR CO., INC. | 11 | 2015–2017 |
| GOLDMAN EDWARDS | 11 | 2020–2022 |
| LUNDBECK LLC | 11 | 2018–2021 |
| PANDORA | 11 | 2015–2017 |
| REGENESIS | 11 | 2020–2022 |
| ADAPT PHARMA INC. | 10 | 2016–2018 |
| BANK OF AMERICA CORPORATION | 10 | 2019–2022 |
| COALITION FOR CANNABIS POLICY, EDUCATION, AND REGULATION | 10 | 2021–2023 |
| INTERSTATE NATURAL GAS ASSOCIATION OF AMERICA | 10 | 2019–2021 |
| SPOTIFY USA INC. | 10 | 2015–2017 |
| LABORATOIRE HRA PHARMA | 9 | 2017–2019 |
| ANNALY CAPITAL MANAGEMENT, INC. | 8 | 2019–2021 |
| CAPITOL SOLUTIONS ON BEHALF OF BIPARTISAN POLICY CENTER ADVOCACY NETWORK, INC. | 8 | 2019–2021 |
| GOBRANDS, INC. | 8 | 2021–2023 |
| ENTERGY SERVICES, LLC | 7 | 2015–2016 |
| EVOLUS BEAUTY | 7 | 2019–2020 |
| LILLY USA, LLC | 7 | 2020–2023 |
| NATIONAL CABLE TELECOMMUNICATIONS ASSOCIATION | 7 | 2016–2017 |
| UNDER ARMOUR, INC. | 7 | 2017–2018 |
| EVOLVA INC. | 6 | 2018 |
| JOBSOHIO | 6 | 2021–2023 |
| ROUNDTABLE ON SUSTAINABLE PALM OIL | 6 | 2021–2022 |
| SANOFI U.S. | 6 | 2019–2020 |
| ANYWHERE REAL ESTATE INC. | 5 | 2022–2023 |
| COALITION FOR APP FAIRNESS | 5 | 2022–2023 |
| CSL BEHRING | 5 | 2021–2022 |
| OUTDOOR INDUSTRY ASSOCIATION | 5 | 2020–2021 |
| ELLIOTT MANAGEMENT CORPORATION | 4 | 2015–2016 |
| LYKOS THERAPEUTICS | 4 | 2023 |
| ADVANCED MICRO DEVICES (AMD) | 3 | 2023 |
| AIRCRAFT OWNERS AND PILOTS ASSOCIATION (AOPA) | 3 | 2015 |
| BELLEROPHON THERAPEUTICS | 3 | 2020 |
| VF SERVICES, LLC | 3 | 2021 |
| EDGENUITY INC. | 2 | 2017 |
| ROBERTI GLOBAL, LLC ON BEHALF OF ASSURED GUARANTY MUNICIPAL CORP. | 2 | 2019 |
| THE SCIENCE COALITION | 2 | 2018 |
| ABYRX, INC. | 1 | 2020 |
| ACTIVEHOURS INC., D/B/A EARNIN | 1 | 2022 |
| ASSOCIATION OF AMERICAN RAILROADS | 1 | 2022 |
| COMMERCIAL REAL ESTATE FINANCIAL COUNCIL | 1 | 2017 |
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per - and polyfluoroalkyl substances (PFAS) legislation.
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per - and polyfluoroalkyl substances (PFAS) legislation; Issues related to section 301 tariffs; and other China issues.
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to clean energy tax credits; Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per- and polyfluoroalkyl substances (PFAS) legislation. Issues related to S.4061/ H.R.7962 - A bill to amend the Energy Policy and Conservation Act to modify the definition of water heater under energy conservation standards, and for other purposes; Issues related to clean energy tax credits (117th Congress). Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related S. 806/H.R. 1721 - Healthy H2O Act.
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to clean energy tax credits; Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related S. 806/H.R. 1721 - Healthy H2O Act.
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per - and polyfluoroalkyl substances (PFAS) legislation.
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to clean energy tax credits; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related S. 806/H.R. 1721 - Healthy H2O Act.
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per - and polyfluoroalkyl substances (PFAS) legislation.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023.
EPA Accountability to Farm Country Act
Client: PELOTON INTERACTIVE, INC. · Firm: FORBES-TATE
Issues pertaining to H.R. 7900 - National Defense Authorization Act for Fiscal Year 2023, including issues related to service member health and wellness.
Pharmacy Benefit Manager Transparency Act of 2023
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Pharmacy Benefit Manager Transparency Act of 2023
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Pharmacy Benefit Manager Transparency Act of 2023
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023.
Pharmacy Benefit Manager Transparency Act of 2023
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023.
Pharmacy Benefit Manager Transparency Act of 2023
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023.
Pharmacy Benefit Manager Transparency Act of 2023
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Pharmacy Benefit Manager Reform Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Pharmacy Benefit Manager Reform Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023.
Pharmacy Benefit Manager Reform Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Pharmacy Benefit Manager Reform Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Pharmacy Benefit Manager Reform Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023.
Pharmacy Benefit Manager Reform Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023.
Modernizing and Ensuring PBM Accountability Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Modernizing and Ensuring PBM Accountability Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Modernizing and Ensuring PBM Accountability Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per - and polyfluoroalkyl substances (PFAS) legislation.
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per - and polyfluoroalkyl substances (PFAS) legislation.
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per - and polyfluoroalkyl substances (PFAS) legislation; Issues related to section 301 tariffs; Issues related to H.R.4521 - America COMPETES Act of 2022 (117th Congress).
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to clean energy tax credits; Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per - and polyfluoroalkyl substances (PFAS) legislation; Issues related to section 301 tariffs; and other China issues.
Issues related S. 806/H.R. 1721 - Healthy H2O Act.
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to clean energy tax credits; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per - and polyfluoroalkyl substances (PFAS) legislation; Issues related to section 301 tariffs; and other China issues.
Issues related S. 806/H.R. 1721 - Healthy H2O Act.
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per - and polyfluoroalkyl substances (PFAS) legislation.
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to clean energy tax credits; Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related S. 806/H.R. 1721 - Healthy H2O Act.
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per- and polyfluoroalkyl substances (PFAS) legislation. Issues related to S.4061/ H.R.7962 - A bill to amend the Energy Policy and Conservation Act to modify the definition of water heater under energy conservation standards, and for other purposes; Issues related to clean energy tax credits (117th Congress). Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
A concurrent resolution expressing the sense of Congress supporting the State of Israel.
Client: NOVARTIS, INC. · Firm: FORBES-TATE
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
A concurrent resolution expressing the sense of Congress supporting the State of Israel.
Client: NOVARTIS, INC. · Firm: FORBES-TATE
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to the implementation of H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). S.4348. - FDASLA Act of 2022 (117th Congress), S.4535 - FDASRA Act of 2022 (117th Congress), H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs (117th Congress).
A concurrent resolution expressing the sense of Congress supporting the State of Israel.
Client: NOVARTIS, INC. · Firm: FORBES-TATE
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
A concurrent resolution expressing the sense of Congress supporting the State of Israel.
Client: NOVARTIS, INC. · Firm: FORBES-TATE
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
A concurrent resolution expressing the sense of Congress supporting the State of Israel.
Client: NOVARTIS, INC. · Firm: FORBES-TATE
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
A concurrent resolution expressing the sense of Congress supporting the State of Israel.
Client: NOVARTIS, INC. · Firm: FORBES-TATE
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
A concurrent resolution expressing the sense of Congress supporting the State of Israel.
Client: NOVARTIS, INC. · Firm: FORBES-TATE
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
A concurrent resolution expressing the sense of Congress supporting the State of Israel.
Client: NOVARTIS, INC. · Firm: FORBES-TATE
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to the implementation of H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). S.4348. - FDASLA Act of 2022 (117th Congress), S.4535 - FDASRA Act of 2022 (117th Congress), H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs (117th Congress).
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 -State Opioid Response Grant Authorization Act of 2021 (117th Congress); H.R 2366/S.1457 - Stop Fentanyl Act (117th Congress), H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 (117th Congress); Issues related to the development, manufacture, and distribution of coronavirus vaccines; FY23 Omnibus appropriations bill (P.L. 117-328) and FY24 appropriations bills, HR 6119 - Further Extending Government Funding Act; Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 (117th Congress); H.R 2366/S.1457 - Stop Fentanyl Act (117th Congress); H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 (117th Congress); Issues related to the development, manufacture, and distribution of coronavirus vaccines; FY23 Omnibus appropriations bill (PL 117-328) and FY24 appropriations bills; Further Extending Government Funding Act (PL 117-70); Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 -State Opioid Response Grant Authorization Act of 2021 (117th Congress); H.R 2366/S.1457 - Stop Fentanyl Act (117th Congress), H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 (117th Congress); Issues related to the development, manufacture, and distribution of coronavirus vaccines; FY23 Omnibus appropriations bill (P.L. 117-328) and FY24 appropriations bills, HR 6119 - Further Extending Government Funding Act; Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
State Opioid Response Grant Authorization Act of 2021
Client: EMERGENT BIOSOLUTIONS · Firm: FORBES-TATE
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 (117th Congress); H.R 2366/S.1457 - Stop Fentanyl Act (117th Congress); H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 (117th Congress); Issues related to the development, manufacture, and distribution of coronavirus vaccines; FY23 Omnibus appropriations bill (PL 117-328) and FY24 appropriations bills; Further Extending Government Funding Act (PL 117-70); Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
State Opioid Response Grant Authorization Act of 2021
Client: EMERGENT BIOSOLUTIONS · Firm: FORBES-TATE
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 -State Opioid Response Grant Authorization Act of 2021 (117th Congress); H.R 2366/S.1457 - Stop Fentanyl Act (117th Congress), H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 (117th Congress); Issues related to the development, manufacture, and distribution of coronavirus vaccines; FY23 Omnibus appropriations bill (P.L. 117-328) and FY24 appropriations bills, HR 6119 - Further Extending Government Funding Act; Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
State Opioid Response Grant Authorization Act of 2021
Client: EMERGENT BIOSOLUTIONS · Firm: FORBES-TATE
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 -State Opioid Response Grant Authorization Act of 2021 (117th Congress); H.R 2366/S.1457 - Stop Fentanyl Act (117th Congress), H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 (117th Congress); Issues related to the development, manufacture, and distribution of coronavirus vaccines; FY23 Omnibus appropriations bill (P.L. 117-328) and FY24 appropriations bills, HR 6119 - Further Extending Government Funding Act; Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
Issues pertaining to prescription drug pricing; Issues related to IPAB; Medicare Part D; Importation of drugs; Issues related to 340b; Issues related to Drug Price Competition and Patent Term Restoration Act (Public Law 98-417). Issues regarding implementation of the CREATES Act of 2019 (Public Law No: 116-94); Issues related to Section 340B of the Public Health Service Act; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to prescription drug user fee agreement; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). Issues related to CMR SAMHSA reauthorization in H.R. 7666 - Restoring Hope for Mental Health and Wellbeing Act of 2022 (117th Congress).
Issues pertaining to prescription drug pricing; Issues related to IPAB; Medicare Part D; Importation of drugs; Issues related to 340b; Issues related to Drug Price Competition and Patent Term Restoration Act (Public Law 98-417). Issues regarding implementation of the CREATES Act of 2019 (Public Law No: 116-94); Issues related to Section 340B of the Public Health Service Act; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to prescription drug user fee agreement; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). Issues related to CMR SAMHSA reauthorization in H.R. 7666 - Restoring Hope for Mental Health and Wellbeing Act of 2022 (117th Congress).
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to the implementation of H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). S.4348. - FDASLA Act of 2022 (117th Congress), S.4535 - FDASRA Act of 2022 (117th Congress), H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs (117th Congress).
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to the implementation of H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). S.4348. - FDASLA Act of 2022 (117th Congress), S.4535 - FDASRA Act of 2022 (117th Congress), H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs (117th Congress).
Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Outreach regarding H.R. 3263 - DHS Medical Countermeasures Act; FY 2024 National Defense Authorization Act - provisions related to biological and chemical defense and access to naloxone; Issues related to H.R. 7681 - Preventing Overdoses and Saving Lives Act 2.0 (117th Congress); H.R. 7666 - Restoring Hope for Mental Health and Well-Being Act of 2022 (117th Congress); Issues related to the implementation of S. 3799 - PREVENT Pandemics Act in H.R. 2617 - Consolidated Appropriations Act, 2023.
Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Outreach regarding H.R. 3263 - DHS Medical Countermeasures Act; FY 2024 National Defense Authorization Act - provisions related to biological and chemical defense and access to naloxone; Issues related to H.R. 7681 - Preventing Overdoses and Saving Lives Act 2.0 (117th Congress); H.R. 7666 - Restoring Hope for Mental Health and Well-Being Act of 2022 (117th Congress); Issues related to the implementation of S. 3799 - PREVENT Pandemics Act in H.R. 2617 - Consolidated Appropriations Act, 2023.
Securing a Strong Retirement Act of 2021
Client: INSURED RETIREMENT INSTITUTE · Firm: FORBES-TATE
Issues related to retirement savings; H.R. 2954 - Securing a Strong Retirement Act of 2021 (117th Congress).
Securing a Strong Retirement Act of 2021
Client: INSURED RETIREMENT INSTITUTE · Firm: FORBES-TATE
Issues related to retirement savings; H.R. 2954 - Securing a Strong Retirement Act of 2021 (117th Congress). Issues related to H.R. 3063 - The Retirement Fairness for Charities and Educational Institutions Act.
Securing a Strong Retirement Act of 2021
Client: INSURED RETIREMENT INSTITUTE · Firm: FORBES-TATE
Issues related to retirement savings; H.R. 2954 - Securing a Strong Retirement Act of 2021 (117th Congress). Issues related to H.R. 3063 - The Retirement Fairness for Charities and Educational Institutions Act.
Securing a Strong Retirement Act of 2021
Client: INSURED RETIREMENT INSTITUTE · Firm: FORBES-TATE
Issues related to retirement savings; H.R. 2954 - Securing a Strong Retirement Act of 2021 (117th Congress).
Issues related to retirement savings; H.R. 2954 - Securing a Strong Retirement Act of 2021 (117th Congress). Issues related to H.R. 3063 - The Retirement Fairness for Charities and Educational Institutions Act.
Issues related to retirement savings; H.R. 2954 - Securing a Strong Retirement Act of 2021 (117th Congress). Issues related to H.R. 3063 - The Retirement Fairness for Charities and Educational Institutions Act.
Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Appropriations funding for Fiscal Year 2022, Further Extending Government Funding Act (PL 117-70); Issues related to the development, manufacture, and distribution of coronavirus vaccines; Outreach regarding H.R. 3263 - DHS Medical Countermeasures Act (117th Congress); FY 2024 National Defense Authorization Act - provisions related to biological and chemical defense and access to naloxone; Issues related to H.R. 7681 - Preventing Overdoses and Saving Lives Act 2.0 (117th Congress); H.R. 7666 - Restoring Hope for Mental Health and Well-Being Act of 2022 (117th Congress); Issues related to the implementation of PREVENT Pandemics Act in Consolidated Appropriations Act, 2023 (PL 117-328).
Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Outreach regarding H.R. 3263 - DHS Medical Countermeasures Act; FY 2024 National Defense Authorization Act - provisions related to biological and chemical defense and access to naloxone; Issues related to H.R. 7681 - Preventing Overdoses and Saving Lives Act 2.0 (117th Congress); H.R. 7666 - Restoring Hope for Mental Health and Well-Being Act of 2022 (117th Congress); Issues related to the implementation of S. 3799 - PREVENT Pandemics Act in H.R. 2617 - Consolidated Appropriations Act, 2023.
Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Outreach regarding H.R. 3263 - DHS Medical Countermeasures Act; FY 2024 National Defense Authorization Act - provisions related to biological and chemical defense and access to naloxone; Issues related to H.R. 7681 - Preventing Overdoses and Saving Lives Act 2.0 (117th Congress); H.R. 7666 - Restoring Hope for Mental Health and Well-Being Act of 2022 (117th Congress); Issues related to the implementation of S. 3799 - PREVENT Pandemics Act in H.R. 2617 - Consolidated Appropriations Act, 2023.
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 (117th Congress); H.R 2366/S.1457 - Stop Fentanyl Act (117th Congress); H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 (117th Congress); Issues related to the development, manufacture, and distribution of coronavirus vaccines; FY23 Omnibus appropriations bill (PL 117-328) and FY24 appropriations bills; Further Extending Government Funding Act (PL 117-70); Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 -State Opioid Response Grant Authorization Act of 2021 (117th Congress); H.R 2366/S.1457 - Stop Fentanyl Act (117th Congress), H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 (117th Congress); Issues related to the development, manufacture, and distribution of coronavirus vaccines; FY23 Omnibus appropriations bill (P.L. 117-328) and FY24 appropriations bills, HR 6119 - Further Extending Government Funding Act; Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 -State Opioid Response Grant Authorization Act of 2021 (117th Congress); H.R 2366/S.1457 - Stop Fentanyl Act (117th Congress), H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 (117th Congress); Issues related to the development, manufacture, and distribution of coronavirus vaccines; FY23 Omnibus appropriations bill (P.L. 117-328) and FY24 appropriations bills, HR 6119 - Further Extending Government Funding Act; Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to supply chain; Issues related to implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Issues related to the semiconductor industry in the FY 2024 National Defense Authorization Act; Issues related to implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Issues related to the implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Issues related to the semiconductor industry in the FY 2024 National Defense Authorization Act; Issues related to implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Issues related to advanced design tax credit; Issues related to implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167), Issues related to research and development tax amortization fix.
Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Issues related to the implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to supply chain; Issues related to implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Issues related to advanced design tax credit; Issues related to implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167), Issues related to research and development tax amortization fix.
Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
United States Innovation and Competition Act of 2021
Client: A.O. SMITH CORPORATION · Firm: FORBES-TATE
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per - and polyfluoroalkyl substances (PFAS) legislation; Issues related to section 301 tariffs; Issues related to H.R.4521 - America COMPETES Act of 2022 (117th Congress).
Preventing Overdoses and Saving Lives Act of 2021
Client: EMERGENT BIOSOLUTIONS · Firm: FORBES-TATE
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 -State Opioid Response Grant Authorization Act of 2021 (117th Congress); H.R 2366/S.1457 - Stop Fentanyl Act (117th Congress), H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 (117th Congress); Issues related to the development, manufacture, and distribution of coronavirus vaccines; FY23 Omnibus appropriations bill (P.L. 117-328) and FY24 appropriations bills, HR 6119 - Further Extending Government Funding Act; Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
Healthcare legislative issues, including Medicare, Medicaid and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, post acute care reform.
Healthcare legislative issues, including Medicare, Medicaid and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, post acute care reform, the Older Americans Act, Intergenerational therapy, and issues related to Medicare requirements for participation.
Healthcare legislative issues, including Medicare, Medicaid and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, and post acute care reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSURED GUARANTY MUNICIPAL CORP. via FORBES-TATE
2023 · third_quarter · Q3
Federal bankruptcy related issues that impact Puerto Rico and/or the municipal bond market; Issues related to Municipal bond policies; Issues related to passive foreign Investment Companies; Issues related to public financing.
Issues regarding Puerto Rico's Medicaid program.
Issues related to tax treatment of passive foreign investment companies.
Issues related to supply chain and logistics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR CANNABIS POLICY, EDUCATION, AND REGULATION via FORBES-TATE
2023 · third_quarter · Q3
Issues pertaining to government-wide federal regulation of cannabis.
Issues pertaining to government-wide federal regulation of cannabis.
Issues pertaining to government-wide federal regulation of cannabis.
Issues pertaining to government-wide federal regulation of cannabis.
Issues pertaining to government-wide federal regulation of cannabis.
Issues pertaining to government-wide federal regulation of cannabis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR APP FAIRNESS via FORBES-TATE
2023 · third_quarter · Q3
Issues related to anti-trust legislation, including S.2710 - Open App Markets Act (117th Congress).
Issues related to anti-trust legislation, including S.2710 - Open App Markets Act (117th Congress).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ANYWHERE REAL ESTATE INC. via FORBES-TATE
2023 · third_quarter · Q3
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
NATIONAL ASSOCIATION OF PROTON THERAPY via FORBES-TATE
2023 · third_quarter · Q3
Issues regarding access to and reimbursement of proton therapy, including through Medicare and Medicare Advantage.
Issues pertaining to veterans' access to proton therapy.
Issues regarding access to proton therapy; Issues regarding the Radiation Oncology Alternative Payment Model (RO APM); Issues related to Medicare Prior Authorization.
LYKOS THERAPEUTICS via FORBES-TATE
2023 · third_quarter · Q3
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
JOBSOHIO via FORBES-TATE
2023 · third_quarter · Q3
Issues related to the implementation of the CHIPS and Science Act of 2022 (PL 117-167).
Issues related to economic development, job creation, job retention, job training, workforce development, and the retention of current business, and recruitment of new business, to Ohio.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INSURED RETIREMENT INSTITUTE via FORBES-TATE
2023 · third_quarter · Q3
Issues related to retirement savings; H.R. 2954 - Securing a Strong Retirement Act of 2021 (117th Congress). Issues related to H.R. 3063 - The Retirement Fairness for Charities and Educational Institutions Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDEPENDENT PHARMACY COOPERATIVE via FORBES-TATE
2023 · third_quarter · Q3
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
ALEXION PHARMACEUTICALS, INC. via FORBES-TATE
2023 · third_quarter · Q3
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to low-volume Diagnosis Related Groups (DRG); Issues related to orphan drug tax credit and issues related to rare disease; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIRPAX PHARMACEUTICALS via FORBES-TATE
2023 · third_quarter · Q3
Issues related to the opioid crisis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MICRO DEVICES (AMD) via FORBES-TATE
2023 · third_quarter · Q3
Issues related to advanced design tax credit; Issues related to implementation of the CHIPS and Science Act of 2022 (PL 117-167); Issues related to research and development tax amortization fix.
Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to implementation of the CHIPS and Science Act of 2022 (PL 117-167).
Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to implementation of the CHIPS and Science Act of 2022 (PL 117-167).
A.O. SMITH CORPORATION via FORBES-TATE
2023 · third_quarter · Q3
Issues related S. 806/H.R. 1721 - Healthy H2O Act.
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to energy efficiency and drinking water policy; Issues related to per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to the definition of water heater under energy conservation standards; Issues related to clean energy tax credits; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169).
2023 · third_quarter · Q3
Issues related to the Supplemental Nutrition Assistance Program.
Issues pertaining to gig economy workers and related status.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2023 · third_quarter · Q3
Healthcare initiatives related to novel antibody technology platform.
Issues related to pandemic preparedness.
Healthcare initiatives related to novel antibody technology platform; Issues related pandemic preparedness.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHRMA via FORBES-TATE
2023 · third_quarter · Q3
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to data exclusivity under the United States Mexico Canada Agreement (USMCA); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues pertaining to prescription drug pricing; Medicare Part D; Importation of drugs; Issues related to 340b; Issues related to Drug Price Competition and Patent Term Restoration Act (PL 98-417); Issues related to Section 340B of the Public Health Service Act; Issues related to Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to CMR SAMHSA reauthorization in H.R. 7666 - Restoring Hope for Mental Health and Wellbeing Act of 2022 (117th Congress).
PELOTON INTERACTIVE, INC. via FORBES-TATE
2023 · third_quarter · Q3
Issues related to commerce, tax, trade and health.
Issues related to commerce, tax, trade and health.
Issues related to service member health and wellness.
NOVARTIS, INC. via FORBES-TATE
2023 · third_quarter · Q3
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to COVID 19 funding for BARDA; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169). S.4348. - FDASLA Act of 2022 (117th Congress), S.4535 - FDASRA Act of 2022 (117th Congress), H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs (117th Congress).
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2023 · third_quarter · Q3
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
STRATHSPEY CROWN HOLDINGS, LLC via FORBES-TATE
2023 · third_quarter · Q3
Issues related to CMS coverage decisions and issues related to healthcare reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LILLY USA, LLC via FORBES-TATE
2023 · third_quarter · Q3
Issues related to Insulin pricing, Issues regarding the 340B Drug Pricing Program.
Issues related to USTR continued deliberation on supporting the extension of WTO TRIPS Waivers to COVID-19 therapeutics and diagnostics.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMERGENT BIOSOLUTIONS via FORBES-TATE
2023 · third_quarter · 3T
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 (117th Congress); H.R 2366/S.1457 - Stop Fentanyl Act (117th Congress); H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 (117th Congress); Issues related to the development, manufacture, and distribution of coronavirus vaccines; FY23 Omnibus appropriations bill (PL 117-328) and FY24 appropriations bills; Further Extending Government Funding Act (PL 117-70); Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Appropriations funding for Fiscal Year 2022, Further Extending Government Funding Act (PL 117-70); Issues related to the development, manufacture, and distribution of coronavirus vaccines; Outreach regarding H.R. 3263 - DHS Medical Countermeasures Act (117th Congress); FY 2024 National Defense Authorization Act - provisions related to biological and chemical defense and access to naloxone; Issues related to H.R. 7681 - Preventing Overdoses and Saving Lives Act 2.0 (117th Congress); H.R. 7666 - Restoring Hope for Mental Health and Well-Being Act of 2022 (117th Congress); Issues related to the implementation of PREVENT Pandemics Act in Consolidated Appropriations Act, 2023 (PL 117-328).
2023 · second_quarter · Q2
Issues pertaining to gig economy workers and related status.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMERGENT BIOSOLUTIONS via FORBES-TATE
2023 · second_quarter · Q2
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 -State Opioid Response Grant Authorization Act of 2021 (117th Congress); H.R 2366/S.1457 - Stop Fentanyl Act (117th Congress), H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 (117th Congress); Issues related to the development, manufacture, and distribution of coronavirus vaccines; FY23 Omnibus appropriations bill (P.L. 117-328) and FY24 appropriations bills, HR 6119 - Further Extending Government Funding Act; Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Outreach regarding H.R. 3263 - DHS Medical Countermeasures Act; FY 2024 National Defense Authorization Act - provisions related to biological and chemical defense and access to naloxone; Issues related to H.R. 7681 - Preventing Overdoses and Saving Lives Act 2.0 (117th Congress); H.R. 7666 - Restoring Hope for Mental Health and Well-Being Act of 2022 (117th Congress); Issues related to the implementation of S. 3799 - PREVENT Pandemics Act in H.R. 2617 - Consolidated Appropriations Act, 2023.
COALITION FOR CANNABIS POLICY, EDUCATION, AND REGULATION via FORBES-TATE
2023 · second_quarter · Q2
Issues pertaining to government-wide federal regulation of cannabis.
Issues pertaining to government-wide federal regulation of cannabis.
Issues pertaining to government-wide federal regulation of cannabis.
COALITION FOR APP FAIRNESS via FORBES-TATE
2023 · second_quarter · Q2
Issues related to anti-trust legislation, including S.2710 - Open App Markets Act (117th Congress).
Issues related to anti-trust legislation, including S.2710 - Open App Markets Act (117th Congress).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIRPAX PHARMACEUTICALS via FORBES-TATE
2023 · second_quarter · Q2
Issues related to the opioid crisis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2023 · second_quarter · Q2
Healthcare initiatives related to novel antibody technology platform.
Healthcare initiatives related to novel antibody technology platform; Issues related pandemic preparedness.
Issues related to pandemic preparedness.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASSURED GUARANTY MUNICIPAL CORP. via FORBES-TATE
2023 · second_quarter · Q2
Federal bankruptcy related issues that impact Puerto Rico and/or the municipal bond market; Issues related to Municipal bond policies; Issues related to passive foreign Investment Companies.
Issues related to tax treatment of passive foreign investment companies.
Issues related to supply chain and logistics.
ANYWHERE REAL ESTATE INC. via FORBES-TATE
2023 · second_quarter · Q2
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2023 · second_quarter · Q2
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALEXION PHARMACEUTICALS, INC. via FORBES-TATE
2023 · second_quarter · Q2
Issues related to healthcare, including drug pricing and Medicare Part D; Issues Related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to low-volume Diagnosis Related Groups (DRG); Issues related to orphan drug tax credit and issues related to rare disease; Issues Related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MICRO DEVICES (AMD) via FORBES-TATE
2023 · second_quarter · Q2
Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to supply chain; Issues related to implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
STRATHSPEY CROWN HOLDINGS, LLC via FORBES-TATE
2023 · second_quarter · Q2
Issues related to CMS coverage decisions and issues related to healthcare reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
A.O. SMITH CORPORATION via FORBES-TATE
2023 · second_quarter · Q2
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per - and polyfluoroalkyl substances (PFAS) legislation; Issues related to section 301 tariffs; and other China issues.
Issues related to energy efficiency and drinking water policy; Issues related to per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to the definition of water heater under energy conservation standards; Issues related to clean energy tax credits; Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
PHRMA via FORBES-TATE
2023 · second_quarter · Q2
Issues related to Direct to Consumer (DTC) Advertising; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues pertaining to prescription drug pricing; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues pertaining to prescription drug pricing; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
PELOTON INTERACTIVE, INC. via FORBES-TATE
2023 · second_quarter · Q2
Issues related to service member and veteran health and wellness, in general.
Issues related to commerce, tax, trade and health.
Issues related to service member health and wellness.
NOVARTIS, INC. via FORBES-TATE
2023 · second_quarter · Q2
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Issues related to prescription drug pricing; issues related to World Trade Organization IP waiver; issues related to pharmaceutical intellectual property; issues related to international trade.
Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
LILLY USA, LLC via FORBES-TATE
2023 · second_quarter · Q2
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease.
Issues related to Insulin pricing, Issues regarding the 340B Drug Pricing Program.
Issues related to USTR continued deliberation on supporting the extension of WTO TRIPS Waivers to COVID-19 therapeutics and diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OPTIONS CLEARING CORPORATION (OCC) via FORBES-TATE
2023 · second_quarter · Q2
Issues related to financial services and tax.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NORTHPORT HEALTH SERVICES via FORBES-TATE
2023 · second_quarter · Q2
Healthcare legislative issues, including Medicare, Medicaid and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, post acute care reform, the Older Americans Act, Intergenerational therapy, and issues related to Medicare requirements for participation.
Healthcare legislative issues, including Medicare, Medicaid and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, and post acute care reform.
Healthcare legislative issues, including Medicare, Medicaid and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, post acute care reform.
NATIONAL ASSOCIATION OF PROTON THERAPY via FORBES-TATE
2023 · second_quarter · Q2
Issues regarding access to proton therapy; Issues regarding the Radiation Oncology Alternative Payment Model (RO APM); Issues related to Medicare Prior Authorization.
Issues pertaining to veterans' access to proton therapy.
Issues regarding access to and reimbursement of proton therapy, including through Medicare and Medicare Advantage.
LYKOS THERAPEUTICS via FORBES-TATE
2023 · second_quarter · Q2
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
JOBSOHIO via FORBES-TATE
2023 · second_quarter · Q2
Issues related to economic development, job creation, job retention, job training, workforce development, and the retention of current business, and recruitment of new business, to Ohio.
Issues related to the implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INSURED RETIREMENT INSTITUTE via FORBES-TATE
2023 · second_quarter · Q2
Issues related to retirement savings; H.R. 2954 - Securing a Strong Retirement Act of 2021 (117th Congress). Issues related to H.R. 3063 - The Retirement Fairness for Charities and Educational Institutions Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDEPENDENT PHARMACY COOPERATIVE via FORBES-TATE
2023 · second_quarter · Q2
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023.
2023 · second_quarter · 2T
General issues and regulations impacting the accounting profession.
General issues and regulations impacting the accounting profession.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via FORBES-TATE
2023 · first_quarter · Q1
Issues pertaining to prescription drug pricing; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related to data exclusivity under the United States Mexico Canada Agreement (USMCA); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related to Direct to Consumer (DTC) Advertising; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
PELOTON INTERACTIVE, INC. via FORBES-TATE
2023 · first_quarter · Q1
Issues related to commerce, tax, trade and health.
Issues pertaining to H.R. 7900 - National Defense Authorization Act for Fiscal Year 2023, including issues related to service member health and wellness.
Issues related to commerce, tax, trade and health.
NOVARTIS, INC. via FORBES-TATE
2023 · first_quarter · Q1
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to the implementation of H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). S.4348. - FDASLA Act of 2022 (117th Congress), S.4535 - FDASRA Act of 2022 (117th Congress), H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs (117th Congress).
LILLY USA, LLC via FORBES-TATE
2023 · first_quarter · Q1
Issues related to Insulin pricing, Issues regarding the 340B Drug Pricing Program.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease.
Issues related to USTR continued deliberation on supporting the extension of WTO TRIPS Waivers to COVID-19 therapeutics and diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Q1
General issues and regulations impacting the accounting profession.
General issues and regulations impacting the accounting profession.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OPTIONS CLEARING CORPORATION (OCC) via FORBES-TATE
2023 · first_quarter · Q1
Issues related to financial services and tax.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NORTHPORT HEALTH SERVICES via FORBES-TATE
2023 · first_quarter · Q1
Healthcare legislative issues, including Medicare, Medicaid and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, and post acute care reform.
Healthcare legislative issues, including Medicare, Medicaid and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, post acute care reform, the Older Americans Act, Intergenerational therapy, and issues related to Medicare requirements for participation.
Healthcare legislative issues, including Medicare, Medicaid and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, post acute care reform.
LYKOS THERAPEUTICS via FORBES-TATE
2023 · first_quarter · Q1
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
NATIONAL ASSOCIATION OF PROTON THERAPY via FORBES-TATE
2023 · first_quarter · Q1
Issues regarding access to proton therapy; including in FY 2024 Labor-HHS-Education Appropriations.
Issues regarding access to proton therapy; Issues regarding the Radiation Oncology Alternative Payment Model (RO APM); Issues related to Medicare Prior Authorization.
Issues regarding access to and reimbursement of proton therapy, including through Medicare and Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
EMERGENT BIOSOLUTIONS via FORBES-TATE
2023 · first_quarter · Q1
Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Outreach regarding H.R. 3263 - DHS Medical Countermeasures Act; FY 2024 National Defense Authorization Act - provisions related to biological and chemical defense and access to naloxone; Issues related to H.R. 7681 - Preventing Overdoses and Saving Lives Act 2.0 (117th Congress); H.R. 7666 - Restoring Hope for Mental Health and Well-Being Act of 2022 (117th Congress); Issues related to the implementation of S. 3799 - PREVENT Pandemics Act in H.R. 2617 - Consolidated Appropriations Act, 2023.
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 -State Opioid Response Grant Authorization Act of 2021 (117th Congress); H.R 2366/S.1457 - Stop Fentanyl Act (117th Congress), H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 (117th Congress); Issues related to the development, manufacture, and distribution of coronavirus vaccines; FY23 Omnibus appropriations bill (P.L. 117-328) and FY24 appropriations bills, HR 6119 - Further Extending Government Funding Act; Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
VIRPAX PHARMACEUTICALS via FORBES-TATE
2023 · first_quarter · Q1
Issues related to the opioid crisis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2023 · first_quarter · Q1
Issues related to pandemic preparedness.
Healthcare initiatives related to novel antibody technology platform.
Healthcare initiatives related to novel antibody technology platform; Issues related pandemic preparedness.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
JOBSOHIO via FORBES-TATE
2023 · first_quarter · Q1
Issues related to economic development, job creation, job retention, job training, workforce development, and the retention of current business, and recruitment of new business, to Ohio.
Issues related to the implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR CANNABIS POLICY, EDUCATION, AND REGULATION via FORBES-TATE
2023 · first_quarter · Q1
Issues pertaining to government-wide federal regulation of cannabis.
Issues pertaining to government-wide federal regulation of cannabis.
Issues pertaining to government-wide federal regulation of cannabis.
COALITION FOR APP FAIRNESS via FORBES-TATE
2023 · first_quarter · Q1
Issues related to anti-trust legislation, including S.2710 - Open App Markets Act (117th Congress).
Issues related to anti-trust legislation, including S.2710 - Open App Markets Act (117th Congress).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2023 · first_quarter · Q1
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INSURED RETIREMENT INSTITUTE via FORBES-TATE
2023 · first_quarter · Q1
Issues related to retirement savings; H.R. 2954 - Securing a Strong Retirement Act of 2021 (117th Congress).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INSURED RETIREMENT INSTITUTE via FORBES-TATE
2023 · first_quarter · Q1
Issues related to retirement savings; H.R. 2954 - Securing a Strong Retirement Act of 2021 (117th Congress).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDEPENDENT PHARMACY COOPERATIVE via FORBES-TATE
2023 · first_quarter · Q1
Issues related to direct and indirect remuneration (DIR) fees; Issues related to provider status and Medicare reimbursement.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSURED GUARANTY MUNICIPAL CORP. via FORBES-TATE
2023 · first_quarter · Q1
Federal bankruptcy related issues that impact Puerto Rico and/or the municipal bond market; Issues related to Municipal bond policies; Issues related to passive foreign Investment Companies.
Issues related to supply chain and logistics.
Issues regarding Puerto Rico's Medicaid program.
STRATHSPEY CROWN HOLDINGS, LLC via FORBES-TATE
2023 · first_quarter · Q1
Issues related to CMS coverage decisions and issues related to healthcare reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ANYWHERE REAL ESTATE INC. via FORBES-TATE
2023 · first_quarter · Q1
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
2023 · first_quarter · Q1
Issues pertaining to gig economy workers and related status.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS, INC. via FORBES-TATE
2023 · first_quarter · Q1
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to low-volume Diagnosis Related Groups (DRG); Issues related to orphan drug tax credit and issues related to rare disease; Issues Related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related to healthcare, including drug pricing and Medicare Part D; Issues Related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MICRO DEVICES (AMD) via FORBES-TATE
2023 · first_quarter · Q1
Issues related to the semiconductor industry in the FY 2024 National Defense Authorization Act; Issues related to implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Issues related to advanced design tax credit; Issues related to implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167), Issues related to research and development tax amortization fix.
A.O. SMITH CORPORATION via FORBES-TATE
2023 · first_quarter · Q1
Issues related S. 806/H.R. 1721 - Healthy H2O Act.
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per- and polyfluoroalkyl substances (PFAS) legislation. Issues related to S.4061/ H.R.7962 - A bill to amend the Energy Policy and Conservation Act to modify the definition of water heater under energy conservation standards, and for other purposes; Issues related to clean energy tax credits (117th Congress). Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related to energy efficiency and drinking water policy; Issues related to per- and polyfluoroalkyl substances (PFAS) legislation. Issues related to the definition of water heater under energy conservation standards. Issues related to clean energy tax credits; Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
LYKOS THERAPEUTICS via FORBES-TATE
2023 · first_quarter · RR
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2022 · fourth_quarter · 4A
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · fourth_quarter · 4T
Health care legislative issues including Medicare, Medicaid, and budget related matters; Issues related to nursing home arbitration, group and concurrent therapy, post acute care reform, and Medicare requirements for participation.
Health care legislative issues including Medicare, Medicaid, and budget related matters; Issues related to nursing home arbitration, group and concurrent therapy, post acute care reform; The Older Americans Act, and intergenerational therapy.
Health care legislative issues including Medicare, Medicaid, and budget related matters; Issues related to nursing home arbitration, group and concurrent therapy, and post acute care reform.
NOVARTIS, INC. via FORBES-TATE
2022 · fourth_quarter · 4A
Issues related to prescription drug pricing; issues related to World Trade Organization IP waiver; issues related to pharmaceutical intellectual property; issues related to international trade.
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). S.4348. - FDASLA Act of 2022, S.4535 - FDASRA Act of 2022, H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs.
2022 · fourth_quarter · Q4
Issues related to legislative and regulatory issues related to gene therapies for hemophilia B.
Issues related to medical related travel and visa allowances.
Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Rx pricing.
COALITION FOR CANNABIS POLICY, EDUCATION, AND REGULATION via FORBES-TATE
2022 · fourth_quarter · Q4
Issues pertaining to government-wide federal regulation of cannabis.
Issues pertaining to government-wide federal regulation of cannabis.
Issues pertaining to government-wide federal regulation of cannabis.
ANYWHERE REAL ESTATE INC. via FORBES-TATE
2022 · fourth_quarter · Q4
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
COALITION FOR APP FAIRNESS via FORBES-TATE
2022 · fourth_quarter · Q4
Issues related to anti-trust legislation, including S.2710 - Open App Markets Act.
Issues related to anti-trust legislation, including S.2710 - Open App Markets Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIRPAX PHARMACEUTICALS via FORBES-TATE
2022 · fourth_quarter · Q4
Issues related to the opioid crisis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2022 · fourth_quarter · Q4
Healthcare initiatives related to novel antibody technology platform.
Issues related to COVID funding.
Healthcare initiatives related to novel antibody technology platform; Issues related to COVID funding.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2022 · fourth_quarter · Q4
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
STRATHSPEY CROWN HOLDINGS, LLC via FORBES-TATE
2022 · fourth_quarter · Q4
Issues related to CMS coverage decisions and issues related to healthcare reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROUNDTABLE ON SUSTAINABLE PALM OIL via FORBES-TATE
2022 · fourth_quarter · Q4
Issues related to food supply chain issues.
Issues related to reducing global deforestation and improving global label standards.
Issues related to reducing deforestation.
OPTIONS CLEARING CORPORATION (OCC) via FORBES-TATE
2022 · fourth_quarter · Q4
Issues related to financial services and tax.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NORTHPORT HEALTH SERVICES via FORBES-TATE
2022 · fourth_quarter · Q4
Healthcare legislative issues, including Medicare, Medicaid and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, post acute care reform, the Older Americans Act, Intergenerational therapy, and issues related to Medicare requirements for participation.
Healthcare legislative issues, including Medicare, Medicaid and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, and post acute care reform.
Healthcare legislative issues, including Medicare, Medicaid and budget issues; Issues related to nursing home arbitration, group and concurrent therapy, post acute care reform.
NATIONAL ASSOCIATION OF PROTON THERAPY via FORBES-TATE
2022 · fourth_quarter · Q4
Issues regarding access to proton therapy; Issues regarding the Radiation Oncology Alternative Payment Model (RO APM); Issues related to Seniors Timely Access to Care Act H.R. 3173 S. 3018; Issues related to Medicare Prior Authorization.
Issues regarding access to proton therapy; Issues regarding the Radiation Oncology Alternative Payment Model (RO APM), including in H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Issues regarding access to proton therapy.
JOBSOHIO via FORBES-TATE
2022 · fourth_quarter · Q4
Issues related to S. 1260 - United States Innovation and Competition Act of 2021, including the H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Issues related to economic development, job creation, job retention, job training, workforce development, and the retention of current business, and recruitment of new business, to Ohio.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INSURED RETIREMENT INSTITUTE via FORBES-TATE
2022 · fourth_quarter · Q4
Issues related to retirement savings; H.R. 2954 - Securing a Strong Retirement Act of 2021.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDEPENDENT PHARMACY COOPERATIVE via FORBES-TATE
2022 · fourth_quarter · Q4
Issues related to direct and indirect remuneration (DIR) fees; Issues related to provider status and Medicare reimbursement.
Issues related to pharmacy regulation, the MAC Transparency Act, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency.
Issues related to pharmacy regulation, the MAC Transparency Act, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Q4
Health care legislative issues including Medicare, Medicaid, and budget related matters; Issues related to nursing home arbitration, group and concurrent therapy, post acute care reform, and Medicare requirements for participation.
Health care legislative issues including Medicare, Medicaid, and budget related matters; Issues related to nursing home arbitration, group and concurrent therapy, post acute care reform; The Older Americans Act, and intergenerational therapy.
Health care legislative issues including Medicare, Medicaid, and budget related matters; Issues related to nursing home arbitration, group and concurrent therapy, and post acute care reform.
2022 · fourth_quarter · Q4
Issues pertaining to gig economy workers and related status.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAYER CORPORATION via FORBES-TATE
2022 · fourth_quarter · 4T
Issues related to drug pricing; Issues related to 340b; Issues related to trade; Issues related to tax; Issues Related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSURED GUARANTY MUNICIPAL CORP. via FORBES-TATE
2022 · fourth_quarter · Q4
Issues regarding Puerto Rico's Medicaid program.
Issues related to supply chain and logistics.
Federal bankruptcy related issues that impact Puerto Rico and/or the municipal bond market; Issues related to Municipal bond policies; Issues related to passive foreign Investment Companies.
ASSOCIATION OF AMERICAN RAILROADS via FORBES-TATE
2022 · fourth_quarter · Q4
Issues related to labor agreement H.J.Res.100 - To provide for a resolution with respect to the unresolved disputes between certain railroads represented by the National Carriers' Conference Committee of the National Railway Labor Conference and certain of their employees (P.L. 117)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
ALEXION PHARMACEUTICALS, INC. via FORBES-TATE
2022 · fourth_quarter · Q4
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to low-volume Diagnosis Related Groups (DRG); Issues related to orphan drug tax credit and issues related to rare disease; Issues Related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related to healthcare, including drug pricing and Medicare Part D; Issues Related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues regarding access to proton therapy; including in FY 2024 Labor-HHS-Education Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the semiconductor industry in the FY 2024 National Defense Authorization Act; Issues related to implementation of the CHIPS and Science Act of 2022 (PL 117-167).
Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to supply chain; Issues related to implementation of the CHIPS and Science Act of 2022 (PL 117-167).
Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to implementation of the CHIPS and Science Act of 2022 (PL 117-167).
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per - and polyfluoroalkyl substances (PFAS) legislation; Issues related to section 301 tariffs; and other China issues.
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per - and polyfluoroalkyl substances (PFAS) legislation.
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to clean energy tax credits; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers.
Issues related to Direct to Consumer (DTC) Advertising; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to commerce, tax, trade and health.
Issues related to commerce, tax, trade and health.
Issues related to service member and veteran health and wellness, in general.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers.
Issues related to prescription drug pricing; Issues related to World Trade Organization IP waiver; Issues related to pharmaceutical intellectual property; Issues related to international trade.
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Issues pertaining to government-wide federal regulation of cannabis.
Issues pertaining to government-wide federal regulation of cannabis.
Issues pertaining to government-wide federal regulation of cannabis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues regarding Puerto Rico's Medicaid program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to advanced design tax credit; Issues related to implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167), Issues related to research and development tax amortization fix.
Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Issues related to the semiconductor industry in the FY 2024 National Defense Authorization Act; Issues related to implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
Issues related S. 806/H.R. 1721 - Healthy H2O Act.
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to clean energy tax credits; Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per - and polyfluoroalkyl substances (PFAS) legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to prescription drug pricing; Issues related to IPAB; Medicare Part D; Importation of drugs; Issues related to 340b; Issues related to Drug Price Competition and Patent Term Restoration Act (Public Law 98-417). Issues regarding implementation of the CREATES Act of 2019 (Public Law No: 116-94); Issues related to Section 340B of the Public Health Service Act; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to prescription drug user fee agreement; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). Issues related to CMR SAMHSA reauthorization in H.R. 7666 - Restoring Hope for Mental Health and Wellbeing Act of 2022 (117th Congress).
Issues related to data exclusivity under the United States Mexico Canada Agreement (USMCA); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to commerce, tax, trade and health.
Issues related to commerce, tax, trade and health.
Issues related to commerce, tax, trade and health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to the implementation of H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). S.4348. - FDASLA Act of 2022 (117th Congress), S.4535 - FDASRA Act of 2022 (117th Congress), H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs (117th Congress).
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues regarding access to proton therapy; including in FY 2024 Labor-HHS-Education Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to prescription drug pricing; Issues related to IPAB; Medicare Part D; Importation of drugs; Issues related to 340b; Issues related to Drug Price Competition and Patent Term Restoration Act (Public Law 98-417). Issues regarding implementation of the CREATES Act of 2019 (Public Law No: 116-94); Issues related to Section 340B of the Public Health Service Act; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to prescription drug user fee agreement; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). Issues related to CMR SAMHSA reauthorization in H.R. 7666 - Restoring Hope for Mental Health and Wellbeing Act of 2022 (117th Congress).
Issues pertaining to prescription drug pricing; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to service member and veteran health and wellness, in general.
Issues related to commerce, tax, trade and health.
Issues related to commerce, tax, trade and health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related to prescription drug pricing; issues related to World Trade Organization IP waiver; issues related to pharmaceutical intellectual property; issues related to international trade.
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Issues pertaining to government-wide federal regulation of cannabis.
Issues pertaining to government-wide federal regulation of cannabis.
Issues pertaining to government-wide federal regulation of cannabis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tax treatment of passive foreign investment companies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to supply chain; Issues related to implementation of H.R. 4346 - CHIPS and Science Act of 2022 (P.L. 117-167).
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per - and polyfluoroalkyl substances (PFAS) legislation; Issues related to section 301 tariffs; Issues related to H.R.4521 - America COMPETES Act of 2022 (117th Congress).
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to clean energy tax credits; Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related to energy efficiency and drinking water policy; Issues related to S. 806/H.R. 1721 - Healthy H2O Act, per - and polyfluoroalkyl substances (PFAS) legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instruction to Committees; COVID 19 therapeutic funding; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Rx pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Customs & Border Protection
Issues pertaining to government-wide federal regulation of cannabis.
Issues pertaining to government-wide federal regulation of cannabis.
Issues pertaining to government-wide federal regulation of cannabis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Issues related to the business of real estate, home ownership, antitrust, privacy, cyber.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to importation issues.
Issues related to improving global labor standards.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to tax treatment of passive foreign investment companies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE